Matthew Galsky, MD, discusses the emergence of ICIs the neoadjuvant setting of bladder cancer.
Matthew D. Galsky, MD
Advertisement
Dr. Galsky is Professor of Medicine, Director of Genitourinary Medical Oncology, Co-Director of the Center of Excellence for Bladder Cancer at The Tisch Cancer Institute, and Associate Director for Translational Research at The Tisch Cancer Institute.
Articles by Matthew D. Galsky, MD
Matthew Galsky, MD, discusses the standing of immune checkpoint inhibitors in bladder cancer.
Matthew Galsky, MD, disusses how the treatment paradigm of bladder cancer has shifted over time.
Applying Real-World Evidence to Individualized Treatment Sequencing in Advanced Urothelial Carcinoma
This segment focuses on how clinicians use real-world evidence to individualize treatment sequencing in advanced urothelial (bladder) cancer, especially when patients do not fit classic clinical trial profiles.
This segment explores how clinicians balance quality of life and survival when using maintenance therapy in advanced urothelial (bladder) carcinoma, while also looking ahead to future treatment directions.
Managing Advanced Urothelial Carcinoma in an Older Patient With Comorbidities: A Clinical Discussion
This segment presents an 84-year-old patient with metastatic urothelial (bladder) cancer, multiple comorbidities, and limited functional status who has completed carboplatin plus gemcitabine with stable disease but notable treatment-related cytopenias.
This segment examines how real-world evidence is used to guide maintenance therapy and treatment sequencing in advanced urothelial (bladder) cancer.
This segment focuses on long-term maintenance therapy for advanced urothelial (bladder) carcinoma, emphasizing both clinical outcomes and real-world patient experience.
This segment explores how long-term survival data and real-world experience inform decisions about maintenance immunotherapy in advanced urothelial (bladder) cancer.
In this segment, the speaker reviews real-world clinical decision-making for advanced urothelial (bladder) carcinoma after first-line platinum-based chemotherapy.
Matthew D. Galsky, MD, discusses data from the phase 3 KEYNOTE-B15 trial in patients with MIBC.
Matthew D. Galsky, MD, unpacks the design of the phase 3 KEYNOTE-B15 in patients with MIBC.
After platinum chemo shrinks metastatic bladder cancer, experts weigh maintenance therapy vs watchful waiting for older patients with comorbidities.
Maintenance immunotherapy reshapes advanced bladder cancer care, extending survival after platinum chemotherapy while easing relapse anxiety with better-tolerated checkpoint blockade options.
Matthew D. Galsky, MD, discusses the background of the phase 3 KEYNOTE-B15 trial in muscle-invasive bladder cancer.
Dr Galsky discusses the FDA approval of neoadjuvant durvalumab plus chemotherapy followed by adjuvant durvalumab monotherapy for MIBC.
Matthew Galsky, MD, discusses the FDA approval of perioperative durvalumab plus chemotherapy for patients with muscle-invasive bladder cancer.
Managing Toxicities in Short- and Long-Term Treatment with ADCs
ByVijayakrishna Gadi, MD, University of Illinois College of Medicine,Susana Campos, MD, MPH,Matthew D. Galsky, MD,Edward Garon, MD, Jonsson Comprehensive Cancer Center at UCLA,Aparna R. Parikh, MD
Published: | Updated:
Vijayakrishna Gadi, MD, PhD, discusses short-term and long-term treatments with ADCs.
Managing ILD and Pneumonitis Risk From ADCs
ByVijayakrishna Gadi, MD, University of Illinois College of Medicine,Susana Campos, MD, MPH,Matthew D. Galsky, MD,Edward Garon, MD, Jonsson Comprehensive Cancer Center at UCLA,Aparna R. Parikh, MD
Published: | Updated:
Vijayakrishna Gadi, MD, PhD, discusses the risk of ILD and pneumonitis from ADCs.
The Potential Role for HER2-Targeted ADCs in Earlier Treatment Lines
ByVijayakrishna Gadi, MD, University of Illinois College of Medicine,Susana Campos, MD, MPH,Matthew D. Galsky, MD,Edward Garon, MD, Jonsson Comprehensive Cancer Center at UCLA,Aparna R. Parikh, MD
Published: | Updated:
Vijayakrishna Gadi, MD, PhD, discusses the role of antibody-drug conjugates in a curative setting.
Overcoming Challenges of Testing for HER2-low Across Solid Tumor Types
ByVijayakrishna Gadi, MD, University of Illinois College of Medicine,Susana Campos, MD, MPH,Matthew D. Galsky, MD,Edward Garon, MD, Jonsson Comprehensive Cancer Center at UCLA,Aparna R. Parikh, MD
Published: | Updated:
A panel of experts discuss the challenges of testing for HER2-low access solid tumor types.
ADCs Targeting HER2+ GU Cancers
ByVijayakrishna Gadi, MD, University of Illinois College of Medicine,Susana Campos, MD, MPH,Matthew D. Galsky, MD,Edward Garon, MD, Jonsson Comprehensive Cancer Center at UCLA,Aparna R. Parikh, MD
Published: | Updated:
A panel of experts discuss if there is a role for HER2-directed ADCs antibody-drug conjugates in GU genitourinary cancers
Impact of ADCs on Brain Metastases
ByVijayakrishna Gadi, MD, University of Illinois College of Medicine,Susana Campos, MD, MPH,Matthew D. Galsky, MD,Edward Garon, MD, Jonsson Comprehensive Cancer Center at UCLA,Aparna R. Parikh, MD
Published: | Updated:
A panel of experts discuss where HER2-directed ADCs antibody-drug conjugates fit into the overall treatment paradigm.
ADCs Targeting HER2+ Lung Cancer
ByVijayakrishna Gadi, MD, University of Illinois College of Medicine,Susana Campos, MD, MPH,Matthew D. Galsky, MD,Edward Garon, MD, Jonsson Comprehensive Cancer Center at UCLA,Aparna R. Parikh, MD
Published: | Updated:
Dr Garon shares insights on the role of ADCs for the treatment of HER2+ lung cancer.
Dr Gadi leads a discussion on recent data on the treatment of HER2-low tumors, including ASCO updates on the DESTINY-Breast06 trial.
ADCs Targeting GI Cancers
ByVijayakrishna Gadi, MD, University of Illinois College of Medicine,Susana Campos, MD, MPH,Matthew D. Galsky, MD,Edward Garon, MD, Jonsson Comprehensive Cancer Center at UCLA,Aparna R. Parikh, MD
Published: | Updated:
Dr Parikh discusses the history of ADCs for treating GI cancers with a focus on the data for T-DXd and its role in treating these cancers.
Dr Campos discusses the potential for T-DXd in other gynecologic cancers and offers an overview of results from the DESTINY-PanTumor02 trial.
Dr Gadi introduces treatment and trial data targeting care for patients diagnosed with HER2+ breast cancer.
Dr Gadi leads a discussion surrounding HER2 mutation and overexpression across various cancer types.
Matthew Galsky, MD, discusses the significance of the FDA approval of frontline nivolumab plus chemotherapy patients with metastatic urothelial carcinoma.
Advertisement
Latest Updated Articles
ADCs Targeting HER2+ Lung CancerPublished: July 12th 2024 | Updated: July 12th 2024
- Assessing HER2 Status Across Tumor Types
June 25th 2024
Advertisement
Advertisement
Trending on OncLive
1
FDA Grants Priority Review to Giredestrant for ER-Positive Early Breast Cancer
2
Bispecific-Based Approaches Highlight Key Multiple Myeloma Data Set to Emerge at EHA 2026
3
Breast Cancer Experts Spotlight Practice-Informing and Thought-Provoking Data From ASCO 2026
4
First-Line Zanubrutinib Is Associated With Improved Real-World Efficacy in Older Patients With CLL
5